Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06768658 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06768658 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 1 participants.
The verdict
NCT06768658, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-951 stays in the blood over time to work out the best dose. * The dose of TAK-951 will be checked to see how much stays in their blood over time. * To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).
Interventions
- DRUG TAK-951
- DRUG TAK-951 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06768658
The ClinicalTrials.gov registry entry for NCT06768658 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-951 is the first listed.
NCT06768658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06768658 about?
NCT06768658 is a clinical study titled "A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)". This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: * To check for side effects from treatment with TAK-951. * To learn how much TAK-951 participants can receive without getting side effects from it. * To check how much TAK-95...
What is the current status of trial NCT06768658?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2022-03-02. Estimated completion is 2023-01-09.
What interventions are being tested in trial NCT06768658?
The interventions under investigation include: TAK-951 (DRUG), TAK-951 Placebo (DRUG).
Who is sponsoring clinical trial NCT06768658?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.